Secukinumab - Novartis

Drug Profile

Secukinumab - Novartis

Alternative Names: AIN-457; Anti-interleukin 17A monoclonal antibody; Cosentyx; KB-03303A; NVP-AIN-457; Scapho

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcon; Novartis
  • Developer Icahn School of Medicine at Mount Sinai; Novartis
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis
  • Registered Pustular psoriasis
  • Phase III Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Phase II Alopecia areata; Atopic dermatitis; Tendon injuries
  • Discontinued Asthma; Crohn's disease; Dry eyes; Multiple sclerosis; Polymyalgia rheumatica; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 16 Feb 2018 Efficacy data from the extension to the phase III SCULPTURE trial in Plaque psoriasis presented at the Annual Meeting of the American Academy of Dermatology (AAD-2018)
  • 08 Feb 2018 US FDA approves label update for secukinumab (Cosentyx®) to include treatment of patients with Scalp psoriasis
  • 16 Jan 2018 Efficacy data from the phase III CLARITY trial released by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top